AbCellera Biologics Inc. [ABCL] Revenue clocked in at $489.10 million, down -25.52% YTD: What’s Next?

Related

AbCellera Biologics Inc. [NASDAQ: ABCL] gained 0.95% or 0.1 points to close at $10.65 with a heavy trading volume of 25502726 shares. The company report on May 10, 2022 that AbCellera Reports Q1 2022 Business Results.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Total revenue of $317 million, compared to $203 million in Q1 2021.

Six program starts in the quarter bringing cumulative total to 84, up 56% from Q1 2021.

It opened the trading session at $10.64, the shares rose to $10.76 and dropped to $10.12, the range by which the price of stock traded the whole day. The daily chart for ABCL points out that the company has recorded -30.84% loss over the past six months. However, it is still -96.49% lower than its most recent low trading price.

If we look at the average trading volume of 2.11M shares, ABCL reached to a volume of 25502726 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about AbCellera Biologics Inc. [ABCL]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABCL shares is $30.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABCL stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

The Benchmark Company have made an estimate for AbCellera Biologics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 21, 2021. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on November 19, 2021, representing the official price target for AbCellera Biologics Inc. stock. Previously, the target price had yet another raise to $45, while SVB Leerink analysts kept a Outperform rating on ABCL stock.

The Average True Range (ATR) for AbCellera Biologics Inc. is set at 0.65, with the Price to Sales ratio for ABCL stock in the period of the last 12 months amounting to 6.14. The Price to Book ratio for the last quarter was 2.51, with the Price to Cash per share for the same quarter was set at 1.94. Price to Free Cash Flow for ABCL in the course of the last twelve months was 18.08.

Trading performance analysis for ABCL stock

AbCellera Biologics Inc. [ABCL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.01. With this latest performance, ABCL shares gained by 46.69% in over the last four-week period, additionally sinking by -30.84% over the last 6 months – not to mention a drop of -49.91% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABCL stock in for the last two-week period is set at 73.23, with the RSI for the last a single of trading hit 80.09, and the three-weeks RSI is set at 67.31 for AbCellera Biologics Inc. [ABCL]. The present Moving Average for the last 50 days of trading for this stock 8.14, while it was recorded at 10.28 for the last single week of trading, and 11.80 for the last 200 days.

AbCellera Biologics Inc. [ABCL]: A deeper dive into fundamental analysis

AbCellera Biologics Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 5.50.

AbCellera Biologics Inc. [ABCL]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABCL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbCellera Biologics Inc. go to 10.00%.

An analysis of insider ownership at AbCellera Biologics Inc. [ABCL]

There are presently around $1,204 million, or 40.30% of ABCL stock, in the hands of institutional investors. The top three institutional holders of ABCL stocks are: CAPITAL WORLD INVESTORS with ownership of 18,267,775, which is approximately -17.159% of the company’s market cap and around 20.40% of the total institutional ownership; ALLIANZ ASSET MANAGEMENT GMBH, holding 11,158,045 shares of the stock with an approximate value of $118.83 million in ABCL stocks shares; and BAILLIE GIFFORD & CO, currently with $117.67 million in ABCL stock with ownership of nearly 209.151% of the company’s market capitalization.

69 institutional holders increased their position in AbCellera Biologics Inc. [NASDAQ:ABCL] by around 24,657,714 shares. Additionally, 57 investors decreased positions by around 16,713,335 shares, while 22 investors held positions by with 71,692,632 shares. The mentioned changes placed institutional holdings at 113,063,681 shares, according to the latest SEC report filing. ABCL stock had 30 new institutional investments in for a total of 9,350,535 shares, while 22 institutional investors sold positions of 2,521,440 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]